A seminal research article titled “Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma” has been published in the high-impact journal Advanced Science, offering important insights into why some neuroblastoma cancers become resistant to treatment.

The Oklahoma State University College of Veterinary Medicine research team, led by Dr. Natarajan Aravindan, includes Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim and Loganayaki Periyasamy.

Researchers identified retinal degeneration protein 3 (RD3) as a critical regulator of tumor behavior.

The study shows that loss of RD3, often triggered by therapy, promotes tumor progression by enhancing cellular plasticity, stem cell–like properties, and suppressing immune response mechanisms. This shift drives cancer cells to become more adaptable and less visible to the immune system.

Importantly, restoring RD3 reversed these effects, re-establishing normal cellular identity and improving immune system recognition and response. The findings highlight RD3 as a promising therapeutic target and suggest new strategies to improve the effectiveness of immunotherapy in high-risk neuroblastoma.

This research provides a significant step forward in understanding treatment resistance and opens the door for more targeted and effective therapies for children with aggressive forms of this disease.